Data from the phase 3 HARMONi-GI1 trial support first-line ivonescimab plus chemotherapy as a new standard of care in advanced biliary tract cancer.
|Slideshows|April 29, 2016
FDA Approves RCC Drug, Prostate Cancer and Smoking Link: April News Roundup
Author(s)Cancer Network Editors
This slide show highlights some of the top stories of the month, including the approval of a new agent for RCC, a study that found declines in prostate cancer deaths have mirrored the declines in smoking rates, and more.
Advertisement
Advertisement
Related to this article
Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.
Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma in CLARITY-Gastric01.
Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.
Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.
Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
3
Apalutamide/ADT Improves EFS vs Surgery Alone in High-Risk Prostate Cancer
4
Divarasib Improves Survival vs Sotorasib or Adagrasib in KRAS G12C+ NSCLC
5